Health Catalyst executive sells over $54k in company stock

Health Catalyst , Inc. (NASDAQ:HCAT) Chief Commercial Officer, Kevin Lee Freeman, recently completed a significant stock transaction, according to the latest regulatory filings. Freeman sold 7,500 shares of Health Catalyst stock at an average price of $7.2232, totaling approximately $54,174.

The sale, reported on September 3, 2024, was executed under a prearranged 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for buying or selling stocks at a time when they are not in possession of material non-public information. This plan was established by Freeman on March 12, 2024.

In addition to the sale, the filing also disclosed that Freeman disposed of 2,772 shares at $7.2691 each, to cover tax withholding obligations associated with the vesting of restricted stock units. This transaction, which is not considered a discretionary trade, amounted to $20,149 and is a common practice for settling tax liabilities resulting from the vesting of equity awards.

Following these transactions, Freeman still holds a substantial number of shares in Health Catalyst, with the post-transaction amount listed as 255,881 shares of common stock. These recent trades provide investors with a glimpse into the stock activity of one of Health Catalyst's top executives, offering a perspective on insider sentiment toward the company's stock performance and value.

Investors often monitor insider buying and selling as it can provide insights into a company's financial health and future prospects. However, it is important to consider that trading activity by executives can be influenced by a variety of factors and may not necessarily reflect their outlook on the company's future performance.

In other recent news, Health Catalyst has been making significant strides in the healthcare data analytics market. The company reported impressive Q2 2024 earnings, with revenue reaching $75.9 million, a 4% year-over-year increase, and adjusted EBITDA hitting $7.5 million. This performance surpassed the company's financial guidance, demonstrating a strong first half of 2024.

Health Catalyst also completed acquisitions worth $61.2 million from May to August, enhancing its market position. Despite one client's bankruptcy proceedings, the company maintains its full-year adjusted EBITDA guidance, indicating resilience in its financial strategy.

Analyst firm Canaccord Genuity maintained a Buy rating and an $11.00 price target on Health Catalyst shares, expressing optimism for the company's growth prospects. In contrast, Piper Sandler reduced the price target to $11 from $14 while retaining an Overweight rating, citing execution questions.

Health Catalyst anticipates a return to double-digit revenue growth in 2025, underpinned by the successful introduction of the Ignite platform and a technology-focused acquisition strategy. These recent developments reflect Health Catalyst's strategic focus and potential for continued growth.

InvestingPro Insights

Health Catalyst, Inc. (NASDAQ:HCAT) has recently been the subject of notable insider trading activity, which can often be a powerful indicator of a company's future direction. In light of these developments, a review of the latest metrics and insights from InvestingPro can provide valuable context for investors.

One of the key InvestingPro Tips for Health Catalyst is that analysts are projecting net income growth for the company this year, which suggests optimism about the company's ability to improve its bottom line. Additionally, despite a challenging period, Health Catalyst holds more cash than debt on its balance sheet, providing it with financial flexibility. These insights may be particularly relevant given the recent insider trading activity, as they offer a broader perspective on the company's financial health and potential for profitability.

Looking at the InvestingPro Data, Health Catalyst's market capitalization stands at $445.06 million, reflecting its current valuation in the market. The company's price-to-earnings (P/E) ratio is negative at -4.97, indicating that it has not been profitable over the last twelve months. However, with a price-to-book (P/B) ratio of 1.25, it suggests that the market may be valuing the company's assets favorably. Moreover, Health Catalyst has experienced a strong return over the last month, with a one-month price total return of 25.25%, potentially signaling growing investor confidence.

For investors seeking more in-depth analysis, there are additional InvestingPro Tips available for Health Catalyst at InvestingPro. These tips can provide a more comprehensive understanding of the company's financial position and future outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.